drugset
drugset / Trial / NCT04109742

Curcumin for Pediatric Nonalcoholic Fatty Liver Disease

NCT04109742 ↗

Phase 2 Withdrawn Columbia University Thorne HealthTech, Inc · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

This is a single-center, randomized, double-blinded, placebo-controlled, parallel treatment groups phase 2a study of curcumin for pediatric nonalcoholic fatty liver disease (NAFLD).

Timeline

Start
2019-12-09
Primary completion
2020-04-22
Completion
2020-04-22

Drugs

EvaluationDrugModalityDoseRoute
Comparator Curcumin Small molecule 500 mg Oral
Comparator Curcumin Small molecule 1000 mg Oral

Indications

NAFLD1 metabolic dysfunction-associated steatohepatitis